Feb 18, 2020
Moleculin Presents Clinical Trial Data Demonstrating a Median Reduction of 56% in Skin Cancer Lesions
Oct 31, 2019
Mallinckrodt Announces UVADEX® (Methoxsalen) Approved in Australia for use with the THERAKOS® CELLEX® Photopheresis System for Treatment of Chronic Graft Versus Host Disease (cGvHD) and Skin Manifestations of Cutaneous T-Cell Lymphoma (CTCL) in Adults
Jun 03, 2019
Kyowa Kirin Presents Post-Hoc Analysis of Pivotal Trial for Poteligeo® (mogamulizumab-kpkc)
Mar 04, 2019
Mallinckrodt Presents New Data on Real-World Resource Utilization Associated with Continuation of Systemic Treatment among Patients with Cutaneous T-cell Lymphoma at 2019 American Academy of Dermatology Annual Meeting
Dec 03, 2018
Kyowa Kirin Presents Additional Analyses of MAVORIC Trial
Aug 10, 2018
Kyowa Hakko Kirin Announces Results of Phase 3 Clinical Study of Mogamulizumab Published in Lancet Oncology
Aug 08, 2018
FDA approves treatment for two rare types of non-Hodgkin lymphoma
Aug 08, 2018
Kyowa Kirin Announces FDA Approval of Poteligeo® (mogamulizumab-kpkc) for the Treatment of Mycosis Fungoides and Sézary Syndrome
Jun 04, 2018
Kyowa Kirin Presents New Data for Mogamulizumab from Its Lead Program in Cutaneous T-cell Lymphoma (CTCL) at ASCO
May 18, 2018
Additional Remetinostat Phase II Data Will be Presented at the International Investigative Dermatology Meeting on May 18 and 19
Dec 11, 2017
Kyowa Hakko Kirin Announces Results of Phase 3 Clinical Study of Mogamulizumab (KW-0761) in Patients with Cutaneous T-cell Lymphoma at the American Society of Hematology 2017
Oct 13, 2017
Remetinostat Phase II Data Demonstrate Efficacy on Skin Lesions, Reduction of Itching and High Tolerability in Patients With Early-stage MF-type CTCL